Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Jiangmen Central Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07583550CT.gov Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06431633CT.gov Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. | — | Recruiting | — | — | — |
NCT06177925CT.gov A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | — | Recruiting | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Jiangmen Central Hospital | P3 | B · 61 |
| Carboplatin | Jiangmen Central Hospital | P3 | BB |
| Ivacaftor | University of British Columbia | P3 | BB |
| Lumacaftor | Vertex Pharmaceuticals Incorporated | P3 | BB |
| Theophylline | NCIC Clinical Trials Group | P3 | BB |
| Pembrolizumab | Sarah Goldberg | P3 | B |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | B |
| Rivoceranib | Sichuan Cancer Hospital and Research Institute | P2 | B |
| Interferon Gamma-1B | InterMune | P3 | B |
+41 more in the Lung Disorder cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Lung Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-lung-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →